Glivec Articles
Small-molecule cancer drug revenues will reach $32.7 billion in 2016, says Visiongain
9 January 2013
Novartis Indian patent hearings close, but no verdict yet
5 December 2012
MSF update on Novartis versus India, Supreme Court case
18 November 2012
Sanofi moves on Lemtrada; Novartis Indian patent case
21 August 2012
Mixed NICE recommendations for CML and diabetes drugs
13 January 2012
UK NICE recommends Novartis drugs for chronic myeloid leukemia, but not Bristol-Myers’ Sprycel
6 December 2011
UK’s NICE asks for more info on Boehringer’s Pradaxa; backs Novartis’ Tasigna but not Glivec or B-MS Sprycel for leukemia
18 August 2011
ASCO highlights include GSK’s pazopanib, Novartis’ INC424 and Glivec, B-MS/Otsuka’s Sprycel
6 June 2011
ASH meeting: Pfizer’s bosutinib disappoints in myeloid leukemia trial; Novartis’ Tasigna beats Glivec in CML study
7 December 2010
Roche convinces UK’s NICE to recommend Herceptin for metastatic gastric cancer; Novartis fail in higher dose Glivec
25 November 2010
UK’s NICE calls for more data on Bristol-Myers/Otsuka’s Abilify for schizophrenia; Scotland backs Novartis’Glivec
14 September 2010
UK’s NICE gives final “no” to NHS use of Novartis cancer drug Glivec; Novartis now holds 77% of Alcon
26 August 2010
UK’s NICE “not minded” to recommend Novartis’ Glivec/Gleevec for GIST patients at risk of recurrence after surgery
24 March 2010
Showing 1-24 of 24 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
